Key result
Protein C concentrate during type 1 deficiency pregnancy yields no thromboembolic events and a healthy birth.
Why the study?
The risks of venous thrombosis and fetal loss are increased in patients with protein C deficiency, and treatment options for those intolerant to heparin are limited.
Does protein C concentrate prevent thromboembolic events and fetal loss in a pregnant patient with type 1 protein C deficiency and heparin intolerance?
Case Report (n=1)
Does protein C concentrate prevent thromboembolic events and fetal loss in a pregnant patient with type 1 protein C deficiency and heparin intolerance?
Protein C concentrate may be a successful and safe therapeutic strategy for preventing thrombosis and fetal loss in pregnant patients with type 1 protein C deficiency who are intolerant to heparin.
No takes yet. Share an insight, caveat, or question.
Protein C concentrate use was associated with uncomplicated pregnancy in one deficient patient; hypothesis-generating, requires confirmation before broader adoption.
Richards et al. (1997) conducted a case report in Type 1 protein C deficiency, previous thrombosis, recurrent fetal loss in pregnancy (n=1). Protein C concentrate was evaluated on Thromboembolic events and birth outcome. Protein C concentrate administered during pregnancy in a patient with type 1 protein C deficiency resulted in no thromboembolic events and the birth of a healthy infant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: